TickerTalks
Browse all tickers →
TickerTalks›$DARE
DADARE

Dare Bioscience, Inc.

$DARE·$11M·Biotechnology·Healthcare
$0.72-2.1%YTD-61.7%1Y-65.8%
Price updated 9h ago·X counts updated 5d ago
DADARE
$DAREDare Bioscience, Inc.
$0.72-2.08%40 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $DARE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

40X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $DARE's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-20

Daré Bioscience posters are riding a sharp move. DARE jumped +60% and is still up +35% after-hours; the stock also did a stock offering that tanked it earlier, framed as a possible entry setup. Bulls flag two direct-sales products just launched in Q3 as a real ramp catalyst, and posters describe DCA adds as their preferred approach. 'This one has quietly become a standout, the kind of persistence that gets noticed.' Bullish.

Read what X is saying about $DARE

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $DARE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Daré Bioscience up 60% intraday with two direct-sales products launching — the HPV patent is the forward optionality.

Daré Bioscience is a women's-health biopharma whose 2026 breakout reflects both specific product-launch catalysts and the HPV-vaccine optionality. Daré just gained a new US Patent strengthening the DARE-HPV program.

  • The P&L is early-commercial: Q2 revenue was $152K (up 500% YoY off a tiny base) at a -1,967% operating margin and EPS of -$0.21, with trailing EPS beats of 32.6% and 39.4% — small-dollar surprises on a company whose stock price is driven by product-launch and regulatory catalysts.
  • The specific catalyst stack is substantive: two direct-sales products just launched in Q3 (ramp catalyst), the newly granted US Patent for DARE-HPV as potential first FDA-approved pharmacologic HPV treatment, and Phase 1 Sildenafil Cream Study publication showing lower systemic exposure vs oral.

At 5% of its 52-week range and 53% below the 200-day going into Nov 12 earnings, the setup is a classic deep-drawdown biotech catalyst coil. A clean product-launch revenue print plus any specific DARE-HPV regulatory-pathway commentary is the trigger; a dilution surprise or any FDA-pathway reset is the invalidation.

Agrees with X sentimentThe +60% intraday move and the direct-sales-product launches are grounded operational signals. The 'DCA adds as preferred approach' framing is honest retail positioning on a sub-$1 microcap.

What to watch: Nov 12 Q3 earnings — direct-sales product revenue, DARE-HPV regulatory-pathway commentary, cash runway, and FY27 guide. Named product-launch revenue plus DARE-HPV progress is the trigger; dilution surprise is the invalidation.

On the calendar: 2026-11-12 — Q3 earnings

event ahead 30dproduct launch catalyst

Read the AI verdict on $DARE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biopharma developing contraception, fertility, and vaginal health products for women, with one FDA-approved drug (XACIATO).

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DARE.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $DARE

Partial — medical device revenue depends on elective procedure volumes and hospital capex; Daré Bioscience, Inc.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-151%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-56.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
15.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
5.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
9.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.20$-0.30+32.6%
Q1 2026May 14, 2026$-0.20$-0.33+39.4%
Q4 2025Mar 26, 2026$-0.02$-0.24+91.7%
Q3 2025Nov 13, 2025$-0.28$-0.33+15.2%
Next earningsThu, Nov 12·consensus EPS $-0.14

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$152K+499.6%-423%-1967%$-0.21$-5.5M
Q4 FY25$1.0M-1708.4%71.1%-144%$-0.10$1.2M
Q3 FY25$2K-94.6%100%-162341%$-0.28$-617K
Q2 FY25$-21K-194.4%100%18080%$-0.45$-5.3M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.7M$248K – $5.2M-$0.78-$1.04 – -$0.522
FY27$8.9M$6.2M – $12.0M-$0.41-$0.61 – -$0.251
FY28$37.1M$28.9M – $45.2M$0.12$0.06 – $0.182
FY29$105.5M$73.3M – $143.4M$1.51$0.91 – $2.211
FY30$240.0M$166.8M – $326.1M$4.87$2.94 – $7.131

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.1%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-25.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-58.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 13.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.015-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 10 other (10 awards) in window

See when $DARE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KListing / delisting noticeOct 28-K — Item 3.01: Listing / delisting notice
8-KPress release / Reg FDOct 18-K — Item 7.01: Press release / Reg FD
AI summary

DARÉ BIOSCIENCE, INC. (DARE) filed a Regulation FD disclosure (8-K Item 7.01) on 2026-10-01. The excerpt shows only the cover page; the actual disclosed material (typically investor presentation slides, a press release, or conference call transcript) is attached as an exhibit. Reg FD events can contain forward-looking statements or updated guidance material to investors.

8-KCharter amendmentSep 118-K — Item 5.03: Charter amendment
AI summary

DARÉ BIOSCIENCE, INC. (DARE) filed an 8-K on 2026-09-11 disclosing an amendment to its articles of incorporation, bylaws, or a change in fiscal year (Item 5.03). These are governance changes that can affect shareholder voting rights, anti-takeover provisions, or reporting cadence — material if they alter capital structure rights or entrench management.

8-KPress release / Reg FDSep 98-K — Item 7.01: Press release / Reg FD
AI summary

DARE BIOSCIENCE, INC. DARÉ BIOSCIENCE, INC. (DARE) filed a Regulation FD disclosure (8-K Item 7.01) on 2026-09-09. The excerpt shows only the cover page; the actual disclosed material (typically investor presentation slides, a press release, or conference call transcript) is attached as an exhibit. Reg FD events can contain forward-looking statements or updated guidance material to investors.

S-1Initial registrationAug 26S-1
AI summary

Daré Bioscience, Inc. (DARE, San Diego CA), a clinical-stage specialty biopharmaceutical company focused on women's reproductive and sexual health, filed a new S-1 registration statement with the SEC on August 26, 2026, with CEO Sabrina Martucci Johnson as agent contact and legal counsel Edwin Astudillo. The S-1 registers securities for a potential public offering, including the specific share count, offering price range, and use of proceeds detailed in the full document. This is a new capital markets registration (not an S-3 shelf), indicating DARE seeks to raise capital for clinical development. The filing represents a meaningful dilution event if the offering proceeds.

8-KMaterial agreementAug 178-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 8.01: Other event
AI summary

Daré Bioscience (DARE) filed an 8-K under Items 1.01, 3.02, 8.01, and 9.01, disclosing a material definitive agreement, issuance of unregistered securities, and other material events effective August 14, 2026. The combination of items indicates a financing transaction, likely a private placement or PIPE. No specific terms were available in the excerpt. Daré Bioscience is a San Diego, CA women's health therapeutics company.

424B5Prospectus supplement (offering)Aug 17424B5
AI summary

Daré Bioscience (DARE) filed a 424B5 prospectus supplement for an offering of 4,085,687 shares of common stock plus 293,894 pre-funded warrants at $1.37 per share ($1.3699 for pre-funded warrants). The pre-funded warrants include a 4.99%/9.99% ownership blocker, allowing investors approaching the threshold to use warrants instead of shares. The offering was part of a concurrent private placement. Daré Bioscience is a San Diego women's health company focused on novel drug delivery platforms.

8-KPress release / Reg FDJul 248-K — Item 7.01: Press release / Reg FD
AI summary

DARE filed an 8-K under Reg FD (Item 7.01), disclosing material non-public information simultaneously to all investors. The disclosure covers: presentation of Daré Bioscience, Inc. This is typically an investor presentation, conference slides, or press release furnished as an exhibit. Reg FD filings ensure equal access to information for all investors; the substantive data is in the attached exhibit.

+ 27 other (8 8-Ks · 5 proxys · 3 253G2s · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunitiesglobenewswire.com·4d agoContrasting RYTHM (NASDAQ:RYM) & Dare Bioscience (NASDAQ:DARE)defenseworld.net·4d agoDare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infectionglobenewswire.com·19d agoDaré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafilglobenewswire.com·33d agoDaré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demandglobenewswire.com·36d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $DARE on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport